{"id":"W2749746182","doi":"10.1016/s1470-2045(17)30578-8","title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"ca_institutions":"CancerCare Manitoba","funders":"Onyx Pharmaceuticals; Amgen","keywords":"Carfilzomib; Bortezomib; Medicine; Interim analysis; Multiple myeloma; Dexamethasone; Proteasome inhibitor; Tolerability; Internal medicine; Refractory (planetary science); Clinical trial; Oncology; Surgery; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006088896,0.001725193,0.00339705,0.0004438031,0.0005087209,0.001932046,0.0009740735,0.002327939,0.004439439],"category_scores_gemma":[0.004041462,0.0005410337,0.003664887,0.0005423664,0.001892424,0.002128522,0.0007580503,0.004023947,0.0009426304],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001315681,"about_ca_system_score_gemma":0.001418708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00124658,"about_ca_topic_score_gemma":0.003134419,"domain_scores_codex":[0.9975693,0.001614515,0.00008840112,0.0002521274,0.0001506803,0.0003250287],"domain_scores_gemma":[0.9967631,0.001407666,0.0005671912,0.0003144538,0.0001601798,0.0007874204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9770904,0.001572312,0.0009280966,0.0002429051,0.001275222,0.00003564854,0.00005632326,0.0005812587,0.001131915,0.0001669071,0.001308417,0.01561054],"study_design_scores_gemma":[0.926241,0.06332015,0.005706734,0.00005621219,0.001424456,0.00008076489,0.0000482318,0.0006408431,0.0004367816,0.0005712516,0.001440153,0.00003347176],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9785696,0.009795321,0.001035929,0.002108804,0.0005309869,0.001306005,0.00251588,0.0001973589,0.003940165],"genre_scores_gemma":[0.9845829,0.002605586,0.001732576,0.002363971,0.0005174419,0.001438377,0.003954935,0.00005435163,0.002749908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006088896,"threshold_uncertainty_score":0.03220153,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2558644524284098,"score_gpt":0.4978180911776169,"score_spread":0.2419536387492071,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}